U.S. markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5270-0.0148 (-2.73%)
At close: 04:00PM EDT
0.5230 -0.00 (-0.76%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close0.5418
Bid0.5200 x 1800
Ask0.5280 x 1800
Day's Range0.5200 - 0.5400
52 Week Range0.4850 - 50.4000
Avg. Volume11,372,293
Market Cap20.565M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agile Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/15/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • Motley Fool

    Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript

    Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook and financing prospects for the future; our outlook for the second half of 2022; management's expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla; our business strategy; our partnership with Afaxys and its ability to promote growth; our product supply agreement with Nurx and its ability to educate patients about Twirla; our connected TV campaign and its ability to promote growth; and our assessment of the combined hormonal contraceptive market in general, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.

  • Benzinga

    Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock

    Maxim Group upgraded Agile Therapeutics Inc (NASDAQ: AGRX) to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound. Agile recently closed an equity offering, raising around $24 million in gross proceeds, and brought in around $12.8 million from its ATM facility. The cash runway should be sufficient into 1Q23. In addition, management is enacting austerity measures and refining its commercial efforts, Maxim notes. Related: HC Wainwright Sees Agile Ther

  • Insider Monkey

    10 Best Penny Stocks to Buy in July

    In this article, we discuss the 10 best penny stocks to buy in July. If you want to see only the absolute top penny stocks to buy this month, check out 5 Best Penny Stocks to Buy in July. Penny stocks are priced under $5 and often represent high-risk public companies that do offer exponential […]